Lineage Cell Therapeutics: Pay

Lineage Cell Therapeutics paid its 3 named executives $4.1M in total in FY2025 (Dec). CEO Brian M. Culley was paid $2.1M of that.

PayNo stock prices for these years
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Brian M. CulleyChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Jill A. HoweChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
George A. Samuel IIIGeneral Counsel and Corporate Secretary
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 10 peers with pay on file was $3.2M. The CEO of Lineage Cell Therapeutics was paid $2.1M, 34% below the median.

  1. 1MeiraGTx Holdings
  2. 2Anaptysbio
  3. 3Cartesian Therapeutics
  4. 4Capricor Therapeutics
  5. 5aTYR Pharma
  6. 6Nkarta
  7. 7Verastem
  8. 8Fate Therapeutics
  9. 9Lineage Cell Therapeutics
  10. 104D Molecular Therapeutics
  11. 11Agenus
  12. 12Adverum Biotechnologies, Inc.Not disclosed
  13. 13Allogene TherapeuticsNot disclosed
  14. 14BioAtla, Inc.Not disclosed
  15. 15Celularity IncNot disclosed
  16. 16Century TherapeuticsNot disclosed
  17. 17Chimerix IncNot disclosed
  18. 18Gritstone bio, Inc.Not disclosed
  19. 19Kyverna Therapeutics IncNot disclosed
  20. 20REGENEXBIO Inc.Not disclosed
  21. 21Sana BiotechnologyNot disclosed
  22. 22Vor BiopharmaNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.